Pure Global Cannabis Inc. (TSXV:PURE; OTC: PRCNF; FRA:1QS) (the “Company” or “Pure Global” or “PURE”), an integrated, growth-oriented life sciences cannabis Company, through its subsidiary PureSinse Inc. (“PureSinse”), is pleased to announce that Health Canada has completed its physical on-site inspection required to issue a sales license to PureSinse.
Pure Global Cannabis Inc. (TSXV:PURE; OTC: PRCNF; FRA:1QS) (the “Company” or “Pure Global” or “PURE”), an integrated, growth-oriented life sciences cannabis Company, through its subsidiary PureSinse Inc. (“PureSinse”), is pleased to announce that Health Canada has completed its physical on-site inspection required to issue a sales license to PureSinse. Upon final approvals over the coming weeks, PureSinse will be granted a sales license under the Cannabis Act, formerly the Access to Cannabis for Medical Purposes Regulations (ACMPR). Possessing this license will qualify PureSinse to supply and sell cannabis products to medical patients, the legal adult markets, and the many local and international markets opening up for psychoactive and non-psychoactive cannabidiol (CBD) products.
In preparation for sales and full launch, the Company will soon be unveiling a new user-friendly eCommerce website that is in final stages of development. Medical cannabis patients will soon be able to register with PureSinse, order medical cannabis online, and enjoy discrete delivery via registered courier. The Company will be offering residents living in the Greater Toronto-Hamilton Area a same-day delivery option, and for medical patients the Company will be absorbing excise taxes, as well as offering compassionate pricing for patients that qualify.
PureSinse continues installation of its vertical farming cultivation systems equipped with automated controlled growth environments for its Phase 2 & 3, within 41,000 square feet of licensed production area, with an anticipated production capacity of minimum 8,000 kilograms. Phase 2 is anticipated to be fully operational by summer 2019, with Phase 3 shortly after.
“We are confident that we have met all the safety, quality assurance, security, and record keeping requirements,” said Malay Panchal, CEO of Pure Global. “The inspection by Health Canada was the one of the last steps prior to issuing a sales license, which will be a significant milestone for the Company enabling sale of cannabis inventories to registered medical patients and provincial distributors, and the initiation of revenues for the Company.”
In keeping with its commitment to continuous improvement and innovation, Pure Global has recently acquired CO2 extraction and high-capacity robotic capsule, oil bottles, and vape pen cartridge filling equipment. The Company continues to build its Brampton campus which will soon be a hub for vertically-farmed cultivation, high capacity extraction, a laboratory for testing, formulations and R&D, and a manufacturing centre of excellence for branded and private label post-derivative products for the wellness, food & beverage, natural health, and pharmaceutical industries.
About Pure Global Cannabis
Pure Global Cannabis Inc. (TSX.V:PURE; OTC:PRCNF; FRA:1QS) is an innovation-based cannabis Company led by experienced pharma, biotechnology, horticultural, consumer packaged goods (CPG), and supply chain experts. The Company’s wholly owned subsidiary, PureSinse Inc., is a licensed producer under the Cannabis Act, 2017. The Company’s Brampton campus houses facilities for vertically farmed cultivation, R&D, extraction, manufacturing, and distribution. PURE will produce branded and white-labeled cannabis products for the medical, pharmaceutical, wellness, health & beauty, natural health, food & beverage, and recreational legal markets with uniquely formulated and purified concentrates. The Company is using the Canadian market as a springboard to develop and manufacture GMP-compliant cannabis products for international sale and distribution with a goal to become one of the most trusted premium international cannabis brands.
This news release contains certain forward-looking statements, including, but not limited to, statements about Pure Global’s future plans and intentions. Wherever possible, words such as “may”, “will”, “should”, “could”, “expect”, “plan”, “intend”, “anticipate”, “believe”, “estimate”, “predict” or “potential” or the negative or other variations of these words, or similar words or phrases, have been used to identify these forward-looking statements. These statements reflect management’s current beliefs and are based on information currently available to management as at the date hereof.
Forward-looking statements involve significant risk, uncertainties and assumptions. Many factors could cause actual results, performance or achievements to differ materially from the results discussed or implied in the forward-looking statements. These factors should be considered carefully and readers should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this news release are based upon what management believes to be reasonable assumptions, Pure Global cannot assure readers that actual results will be consistent with these forward-looking statements. These forward-looking statements are made as of the date of this news release, and Pure Global assumes no obligation to update or revise them to reflect new events or circumstances, except as required by law.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release.
For further information: regarding Pure Global, please contact: Stephen Pynn, VP Corporate Development, Telephone: 1-866-899-PURE (7873), E-mail: email@example.com; Malay (Mel) Panchal, President & CEO, Telephone: 1-866-899-PURE (7873), E-mail: firstname.lastname@example.org